Physician profile
Peter A Mcsweeney
NPI 1881678449
$125,582.67
in general payments reported to CMS, 2019-2025
20 companies · $83.91 in 2025
The $83.91 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $2,227 · 2021: $2,488 · 2022: $66K · 2023: $29K · 2024: $35.18 · 2025: $83.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Travel and Lodging: $2,731 · Consulting Fee: $2,360 · Food and Beverage: $622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,170.00 |
| Travel and Lodging | $2,731.46 |
| Consulting Fee | $2,360.00 |
| Food and Beverage | $622.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $122,335.40 | 2019-2023 | Yescarta |
| Tg Therapeutics, INC. | $1,986.51 | 2021 | |
| Novartis Pharmaceuticals Corporation | $624.92 | 2019-2021 | |
| Abbvie INC. | $142.19 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $62.63 | 2019 | |
| Genzyme Corporation | $57.38 | 2019-2022 | |
| Gilead Sciences, INC. | $52.75 | 2019-2022 | |
| Celgene Corporation | $42.67 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $41.49 | 2019 | |
| Jazz Pharmaceuticals INC. | $33.93 | 2019 | |
| Genentech USA, INC. | $32.30 | 2019 | |
| Incyte Corporation | $30.45 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $29.49 | 2021 | |
| Pfizer INC. | $26.82 | 2019-2020 | |
| Mesoblast, INC. | $23.21 | 2025 | Ryoncil |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $17.32 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.17 | 2019 | |
| Merck Sharp & Dohme LLC | $13.80 | 2019 | |
| Janssen Biotech, INC. | $12.24 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mcsweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.